Richard John Drew
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Richard John Drew has a total of 164 co-authors. Here are the top co-authors by number of shared publications:
Maeve Eogan
11 shared publicationsNaomi McCallion
Department of Neonatology, Rotunda Hospital, Parnell Square, Dublin 1, Ireland
6 shared publications- Maeve Eogan
The Rotunda Hospital Dublin 1 Ireland
4 shared publications Robert Cunney
Department of Microbiology, Children’s Health Ireland at Temple Street , Dublin , Ireland
4 shared publications- Daniel O'REilly
School of Biomolecular and Biomedical Science, University College Dublin, Dublin, Ireland
3 shared publications Wendy Ferguson
Paediatrics, Rotunda Hospital, Dublin, Ireland
3 shared publications
Latest Publications
- Open Access
- 26 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11) , e70491
Investigation of Torque Teno Virus Loads as a Marker of Immunosuppression in Pediatric Chronic Renal Failure: A Pilot Study
Background: Torque Teno Virus (TTV), family Anelloviridae , is a small, non‐enveloped, single‐stranded DNA virus that has not been linked with any specific human illness but nevertheless constitutes a major component of the human virome. An association between TTV loads and the immune status of the host with reference to other viral infections, immunosuppression therapy, and acute rejection is reported in adult and pediatric kidney transplant recipients. We sought to investigate the feasibility of TTV as a surrogate marker of the degree of immunosuppression in pediatric kidney transplant patients. Methods: 185 children attending the Nephrology clinic in Children's Health Ireland at Temple Street were studied over a four‐year period from September 2019 until November 2023, ranging from 0 to 17 years of age. Patients were enrolled from pre‐transplant undergoing kidney replacement therapy ( n = 12), from post‐transplant ( n = 124) groups, and from patients with chronic renal failure ( n = 20) (without kidney replacement therapy), all of which were compared to controls ( n = 35). TTV loads were quantified using a standardized TTV R‐gene kit. Results: TTV loads were significantly higher compared to controls from 3 months post‐transplantation onward ( p < 0.001), with the greatest increase observed between 3 and 6 months post‐transplantation. Immunosuppression exerted a significant independent effect on TTV loads after adjusting for age ( p < 0.001). Overall, females exhibited significantly higher TTV loads than males ( p = 0.01). Furthermore, a significant interaction was observed between patient group and gender ( p < 0.001). Conclusion: These findings suggest that both immunosuppressive status and gender‐related factors contribute to TTV kinetics after transplantation and should be considered when interpreting TTV as a biomarker of immune function. Larger studies are required to confirm our findings.
- 26 October 2026
- Published by Wiley in Pediatric Transplantation
- Vol. 30 (11) , e70491
Open AccessInvestigation of Torque Teno Virus Loads as a Marker of Immunosuppression in Pediatric Chronic Renal Failure: A Pilot Study
Background: Torque Teno Virus (TTV), family Anelloviridae , is a small, non‐enveloped, single‐stranded DNA virus that has not been linked with any specific human illness but nevertheless constitutes a major component of the human virome. An association between TTV loads and the immune status of the host with reference to other viral infections, immunosuppression therapy, and acute rejection is reported in adult and pediatric kidney transplant recipients. We sought to investigate the feasibility of TTV as a surrogate marker of the degree of immunosuppression in pediatric kidney transplant patients. Methods: 185 children attending the Nephrology clinic in Children's Health Ireland at Temple Street were studied over a four‐year period from September 2019 until November 2023, ranging from 0 to 17 years of age. Patients were enrolled from pre‐transplant undergoing kidney replacement therapy ( n = 12), from post‐transplant ( n = 124) groups, and from patients with chronic renal failure ( n = 20) (without kidney replacement therapy), all of which were compared to controls ( n = 35). TTV loads were quantified using a standardized TTV R‐gene kit. Results: TTV loads were significantly higher compared to controls from 3 months post‐transplantation onward ( p < 0.001), with the greatest increase observed between 3 and 6 months post‐transplantation. Immunosuppression exerted a significant independent effect on TTV loads after adjusting for age ( p < 0.001). Overall, females exhibited significantly higher TTV loads than males ( p = 0.01). Furthermore, a significant interaction was observed between patient group and gender ( p < 0.001). Conclusion: These findings suggest that both immunosuppressive status and gender‐related factors contribute to TTV kinetics after transplantation and should be considered when interpreting TTV as a biomarker of immune function. Larger studies are required to confirm our findings.
- Open Access
Proteomic and extracellular particle changes in preterm neonates with suspected late-onset sepsis
- Open Access
Continued genomic surveillance of Vibrio cholerae O1 isolates from cholera cases in Europe, 2023–2024
Background: Following the global resurgence of cholera in 2022, 51 cholera cases were reported by European countries. We previously characterised 49 Vibrio cholerae O1 isolates from these cases using whole genome sequencing. In 2023 and 2024, 59 additional cholera cases were reported by 11 European countries. Aim: We aimed to confirm that V. cholerae O1 isolates associated with cholera cases reported in Europe in 2023–2024 belonged to the epidemic seventh pandemic El Tor (7PET) lineage rather than to non-epidemic V. cholerae O1 lineages, and to characterise their virulence, antimicrobial resistance (AMR) determinants and phylogenetic relationships. Methods: Fifty V. cholerae O1 isolates were available for whole genome sequencing, of which 49 yielded genomes of sufficient quality for analysis. Genomes were analysed together with more than 1,500 publicly available 7PET genomes to place the European isolates into a global phylogenetic context. Results: All 49 genomes belonged to the 7PET lineage and Wave 3. Four sub-lineages were identified: BD1.2 (2/49), AFR12 (6/49), AFR13 (8/49) and Pre-AFR15 (33/49). The predominance of Pre-AFR15 confirms its continued contribution to the ongoing global cholera resurgence. In contrast to our 2022 survey, eight highly drug-resistant AFR13 isolates were detected, documenting the international spread of this highly drug-resistant clone resistant to multiple first-line antimicrobial agents. Conclusion: Whole genome sequencing should be routinely used by reference laboratories to distinguish epidemic 7PET from non-epidemic V. cholerae O1 lineages and to monitor the emergence and international spread of AMR clones. Continued collaborative genomic surveillance of travel-associated cholera cases can provide early insights into the emergence, international spread and antimicrobial resistance of 7PET sub-lineages.
Open AccessContinued genomic surveillance of Vibrio cholerae O1 isolates from cholera cases in Europe, 2023–2024
Background: Following the global resurgence of cholera in 2022, 51 cholera cases were reported by European countries. We previously characterised 49 Vibrio cholerae O1 isolates from these cases using whole genome sequencing. In 2023 and 2024, 59 additional cholera cases were reported by 11 European countries. Aim: We aimed to confirm that V. cholerae O1 isolates associated with cholera cases reported in Europe in 2023–2024 belonged to the epidemic seventh pandemic El Tor (7PET) lineage rather than to non-epidemic V. cholerae O1 lineages, and to characterise their virulence, antimicrobial resistance (AMR) determinants and phylogenetic relationships. Methods: Fifty V. cholerae O1 isolates were available for whole genome sequencing, of which 49 yielded genomes of sufficient quality for analysis. Genomes were analysed together with more than 1,500 publicly available 7PET genomes to place the European isolates into a global phylogenetic context. Results: All 49 genomes belonged to the 7PET lineage and Wave 3. Four sub-lineages were identified: BD1.2 (2/49), AFR12 (6/49), AFR13 (8/49) and Pre-AFR15 (33/49). The predominance of Pre-AFR15 confirms its continued contribution to the ongoing global cholera resurgence. In contrast to our 2022 survey, eight highly drug-resistant AFR13 isolates were detected, documenting the international spread of this highly drug-resistant clone resistant to multiple first-line antimicrobial agents. Conclusion: Whole genome sequencing should be routinely used by reference laboratories to distinguish epidemic 7PET from non-epidemic V. cholerae O1 lineages and to monitor the emergence and international spread of AMR clones. Continued collaborative genomic surveillance of travel-associated cholera cases can provide early insights into the emergence, international spread and antimicrobial resistance of 7PET sub-lineages.
- Open Access
- 26 August 2026
- Published by Elsevier in SSRN Electronic Journal
Impact of fetal inflammatory response syndrome in infants born <32 weeks corrected gestational age on neurodevelopmental outcomes – a retrospective cohort study
Aim:This retrospective multi-site cohort study examined the association between FIRS and neurodevelopmental outcomes in infants born <32 weeks’ gestation. Preterm infants are highly vulnerable to inflammation-mediated brain injury, yet the long-term impact of histological FIRS remains unclear.Methods:Preterm infants (n=955) born between 2018 and 2022 in two tertiary maternity hospitals in Dublin, Ireland were included. FIRS and its severity were defined according to the Amsterdam Placental Workshop Group Consensus Statement. The primary outcome was a composite of death or neurodevelopmental impairment (NDI) at 22–26 months’ corrected age, assessed using Bayley-III scores.Results:Of the cohort, 27.9% were exposed to FIRS. Exposed infants were born at earlier gestations and lower birth weights. After adjustment for gestational age and birth weight, FIRS was not associated with increased odds of death or moderate NDI (OR 0.784, 95% CI 0.547–1.123). Severe FIRS (stage ≥2) was associated with reduced odds of severe NDI or death (OR 0.651, 95% CI 0.438–0.968, p = 0.034). Mortality was 12.15%, and follow-up data were available for 51.7% of infants.Conclusions:Histological FIRS was not associated with adverse early neurodevelopmental outcomes and may be linked to improved outcomes in severe cases, warranting further long-term investigation.
- 26 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessImpact of fetal inflammatory response syndrome in infants born <32 weeks corrected gestational age on neurodevelopmental outcomes – a retrospective cohort study
Aim:This retrospective multi-site cohort study examined the association between FIRS and neurodevelopmental outcomes in infants born <32 weeks’ gestation. Preterm infants are highly vulnerable to inflammation-mediated brain injury, yet the long-term impact of histological FIRS remains unclear.Methods:Preterm infants (n=955) born between 2018 and 2022 in two tertiary maternity hospitals in Dublin, Ireland were included. FIRS and its severity were defined according to the Amsterdam Placental Workshop Group Consensus Statement. The primary outcome was a composite of death or neurodevelopmental impairment (NDI) at 22–26 months’ corrected age, assessed using Bayley-III scores.Results:Of the cohort, 27.9% were exposed to FIRS. Exposed infants were born at earlier gestations and lower birth weights. After adjustment for gestational age and birth weight, FIRS was not associated with increased odds of death or moderate NDI (OR 0.784, 95% CI 0.547–1.123). Severe FIRS (stage ≥2) was associated with reduced odds of severe NDI or death (OR 0.651, 95% CI 0.438–0.968, p = 0.034). Mortality was 12.15%, and follow-up data were available for 51.7% of infants.Conclusions:Histological FIRS was not associated with adverse early neurodevelopmental outcomes and may be linked to improved outcomes in severe cases, warranting further long-term investigation.
- 26 August 2026
- Published by S. Karger AG in Neonatology
- p. 1
The Impact of Histopathological Foetal Inflammatory Response Syndrome on Acute Neonatal Outcomes: A Multisite Cohort Study
Intro: Foetal inflammatory response syndrome (FIRS) has previously been associated with poor acute outcomes in preterm neonates but has been defined inconsistently. In this large retrospective cohort study, we sought to examine the impact of histopathological FIRS on acute clinical outcomes in very preterm neonates. Methods: This was a two-site cohort study based in tertiary maternity units in Dublin, Ireland. Admitted neonates with placental histology and without congenital anomalies <32 weeks-corrected gestational age born between 2018 and 2022 (n = 955) were assessed for exposure to Amsterdam consensus guideline-defined FIRS and consequent acute neonatal outcomes by both univariate and multivariate methods. Results: While univariate analysis showed an increased incidence of death and bronchopulmonary dysplasia (BPD), multivariate analysis adjusting for gestational age and birth weight demonstrated that very preterm neonates exposed to histopathological FIRS are at a lower risk of BPD, composite death or BPD, and respiratory distress syndrome requiring surfactant. Neonates exposed to FIRS were born earlier and smaller than their peers who were not, and when adjusting for gestational age there was no increase in odds of severe intraventricular haemorrhage, days of mechanical ventilation, or diagnosis of sepsis. Conclusions: Very preterm neonates exposed to FIRS are at lower risk of developing death or BPD and requiring surfactant when adjusting for age and birth weight. No other acute outcomes were statistically significantly different.
- 26 August 2026
- Published by S. Karger AG in Neonatology
- p. 1
The Impact of Histopathological Foetal Inflammatory Response Syndrome on Acute Neonatal Outcomes: A Multisite Cohort Study
Intro: Foetal inflammatory response syndrome (FIRS) has previously been associated with poor acute outcomes in preterm neonates but has been defined inconsistently. In this large retrospective cohort study, we sought to examine the impact of histopathological FIRS on acute clinical outcomes in very preterm neonates. Methods: This was a two-site cohort study based in tertiary maternity units in Dublin, Ireland. Admitted neonates with placental histology and without congenital anomalies <32 weeks-corrected gestational age born between 2018 and 2022 (n = 955) were assessed for exposure to Amsterdam consensus guideline-defined FIRS and consequent acute neonatal outcomes by both univariate and multivariate methods. Results: While univariate analysis showed an increased incidence of death and bronchopulmonary dysplasia (BPD), multivariate analysis adjusting for gestational age and birth weight demonstrated that very preterm neonates exposed to histopathological FIRS are at a lower risk of BPD, composite death or BPD, and respiratory distress syndrome requiring surfactant. Neonates exposed to FIRS were born earlier and smaller than their peers who were not, and when adjusting for gestational age there was no increase in odds of severe intraventricular haemorrhage, days of mechanical ventilation, or diagnosis of sepsis. Conclusions: Very preterm neonates exposed to FIRS are at lower risk of developing death or BPD and requiring surfactant when adjusting for age and birth weight. No other acute outcomes were statistically significantly different.
- 24 November 2025
- Published by Taylor & Francis in Infectious Diseases
- Vol. 58 (2) , 175-188
The utility of T. pallidum PCR testing in the diagnosis of congenital syphilis: a systematic review
Congenital syphilis (CS) due to maternal transmission of Treponema pallidum is rising. The interpretation of conventional diagnostic methods is complicated by maternal antibody transfer. Polymerase Chain Reaction (PCR) syphilis testing has been widely studied in adults. PCR is reliable, fast, and can be performed on a variety of sample types. This systematic review aimed to evaluate existing data and summarise current international recommendations on the use of PCR testing on placental and neonatal samples for the diagnosis of CS. A systematic search of PubMed, Ovid MEDLINE, and Cochrane databases was conducted, alongside an internet search of international congenital syphilis guidelines. The review was performed based on the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA statement. The review was registered on the International Prospective Register of Systematic Reviews (PROSPERO). Studies reporting PCR testing on placental or neonatal samples in infants born to mothers with syphilis were included. Guidelines with specific recommendations for congenital syphilis PCR testing were included. Of 221 studies screened, 21 were included, comprising 146 placental and 828 neonatal PCR samples. Only 4 multicentre studies were included. 8 studies included 5 or fewer PCR samples, including 5 single-patient case reports. Five international guidelines were included; all reserved PCR's application for high-risk infants with no clear guidance for low-risk infants. PCR shows promise as an adjunct diagnostic tool for congenital syphilis. However, evidence remains limited. Multicentre diagnostic accuracy studies are urgently needed to inform international recommendations and optimise diagnostic strategies.
- 24 November 2025
- Published by Taylor & Francis in Infectious Diseases
- Vol. 58 (2) , 175-188
The utility of T. pallidum PCR testing in the diagnosis of congenital syphilis: a systematic review
Congenital syphilis (CS) due to maternal transmission of Treponema pallidum is rising. The interpretation of conventional diagnostic methods is complicated by maternal antibody transfer. Polymerase Chain Reaction (PCR) syphilis testing has been widely studied in adults. PCR is reliable, fast, and can be performed on a variety of sample types. This systematic review aimed to evaluate existing data and summarise current international recommendations on the use of PCR testing on placental and neonatal samples for the diagnosis of CS. A systematic search of PubMed, Ovid MEDLINE, and Cochrane databases was conducted, alongside an internet search of international congenital syphilis guidelines. The review was performed based on the Preferred Reporting Items for a Systematic Review and Meta-analysis of Diagnostic Test Accuracy Studies: The PRISMA-DTA statement. The review was registered on the International Prospective Register of Systematic Reviews (PROSPERO). Studies reporting PCR testing on placental or neonatal samples in infants born to mothers with syphilis were included. Guidelines with specific recommendations for congenital syphilis PCR testing were included. Of 221 studies screened, 21 were included, comprising 146 placental and 828 neonatal PCR samples. Only 4 multicentre studies were included. 8 studies included 5 or fewer PCR samples, including 5 single-patient case reports. Five international guidelines were included; all reserved PCR's application for high-risk infants with no clear guidance for low-risk infants. PCR shows promise as an adjunct diagnostic tool for congenital syphilis. However, evidence remains limited. Multicentre diagnostic accuracy studies are urgently needed to inform international recommendations and optimise diagnostic strategies.
- 15 March 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 166 (1) , 27-34
Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines
Background: Mycoplasma genitalium is an emerging pathogen, which has been linked to cervicitis, urethritis and pelvic inflammatory disease (PID). With the advent of multiplex polymerase chain reaction (PCR) panels for sexually transmitted infections, it is increasingly being identified in pregnant women.Objectives: The aim was to review international guidelines, which had explicit recommendations for treatment of M. genitalium infection in pregnancy and breastfeeding.Search Strategy: PubMed, EMBASE and Cochrane databases were reviewed with no age, species, language or date restrictions.Selection Criteria: Studies were included if they had an explicit recommendation for treatment of M. genitalium in pregnancy. Studies were excluded if there was no recommendation in pregnancy, if they referred to other international guideline recommendations or were historical versions of guidelines.Data Collection and Analysis: References were manually reviewed and 50 papers were selected for review. Only four guidelines were included in the final analysis and they were from Europe, UK, Australia and Aotearoa New Zealand.Main Results: All studies recommended azithromycin as first‐line treatment, and advised against moxifloxacin use. The dosing schedule of azithromycin, varied between guidelines, as did the utility/safety of pristinamycin for macrolide resistant infections. Safety data was generally reassuring for azithromycin but inconsistent for pristinamycin.Conclusions: Azithromycin is the first‐line treatment for macrolide susceptible or unknown resistance infections, but there is a lack of consistency regarding dosing of azithromycin or the utility/safety of pristinamycin for macrolide resistant infections in pregnancy/lactation.
- 15 March 2024
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 166 (1) , 27-34
Treatment of Mycoplasma genitalium infection in pregnancy: A systematic review of international guidelines
Background: Mycoplasma genitalium is an emerging pathogen, which has been linked to cervicitis, urethritis and pelvic inflammatory disease (PID). With the advent of multiplex polymerase chain reaction (PCR) panels for sexually transmitted infections, it is increasingly being identified in pregnant women.Objectives: The aim was to review international guidelines, which had explicit recommendations for treatment of M. genitalium infection in pregnancy and breastfeeding.Search Strategy: PubMed, EMBASE and Cochrane databases were reviewed with no age, species, language or date restrictions.Selection Criteria: Studies were included if they had an explicit recommendation for treatment of M. genitalium in pregnancy. Studies were excluded if there was no recommendation in pregnancy, if they referred to other international guideline recommendations or were historical versions of guidelines.Data Collection and Analysis: References were manually reviewed and 50 papers were selected for review. Only four guidelines were included in the final analysis and they were from Europe, UK, Australia and Aotearoa New Zealand.Main Results: All studies recommended azithromycin as first‐line treatment, and advised against moxifloxacin use. The dosing schedule of azithromycin, varied between guidelines, as did the utility/safety of pristinamycin for macrolide resistant infections. Safety data was generally reassuring for azithromycin but inconsistent for pristinamycin.Conclusions: Azithromycin is the first‐line treatment for macrolide susceptible or unknown resistance infections, but there is a lack of consistency regarding dosing of azithromycin or the utility/safety of pristinamycin for macrolide resistant infections in pregnancy/lactation.
- Open Access
- 5 March 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (2) , dlae038
Where to start? The Irish Emergency Department Antimicrobial Discharge (EDAD) study: a multicentre, prospective cohort analysis
Objectives: To determine the percentage of patients across Ireland who are discharged from the Emergency Department (ED) with an antimicrobial prescription, the indication, classification of infections, and guideline compliance. To identify potential areas for antimicrobial stewardship (AMS) interventions in the ED. Patients and methods: A multicentre, prospective cohort analysis study in EDs across eight hospitals in Ireland. At each site, patients aged 1 month and older who presented to the ED and were discharged directly from the ED were included. A random selection of records of patients discharged from the ED were reviewed until a minimum of 30 records with an infection diagnosis resulting in an antibiotic prescription were obtained per hospital. The number of patient discharges with no antibiotic prescriptions were included to calculate the denominator. The indication, infection classification and guideline compliance data were collected on the 30 prescriptions in the participating hospitals. Results: A total of 2619 patient records were reviewed. Of these, 249 (9.5%) patients were discharged with antimicrobial prescriptions from the ED. Most (158; 63%) were classified as probable bacterial infection, 21 (8%) as probable viral, and 18 (7%) had no documented evidence of infection. Three indications accounted for 73% of antimicrobial prescriptions: skin/soft tissue infection; ear, nose and throat infection; and urinary tract infection. Overall guideline compliance was 64%. Conclusions: Several areas for AMS interventions to optimize antimicrobial prescribing in the ED were identified, including targeted local and national guideline reviews, delayed prescribing, improved point-of-care testing and prescriber and patient education.
- 5 March 2024
- Published by Oxford University Press (OUP) in JAC-Antimicrobial Resistance
- Vol. 6 (2) , dlae038
Open AccessWhere to start? The Irish Emergency Department Antimicrobial Discharge (EDAD) study: a multicentre, prospective cohort analysis
Objectives: To determine the percentage of patients across Ireland who are discharged from the Emergency Department (ED) with an antimicrobial prescription, the indication, classification of infections, and guideline compliance. To identify potential areas for antimicrobial stewardship (AMS) interventions in the ED. Patients and methods: A multicentre, prospective cohort analysis study in EDs across eight hospitals in Ireland. At each site, patients aged 1 month and older who presented to the ED and were discharged directly from the ED were included. A random selection of records of patients discharged from the ED were reviewed until a minimum of 30 records with an infection diagnosis resulting in an antibiotic prescription were obtained per hospital. The number of patient discharges with no antibiotic prescriptions were included to calculate the denominator. The indication, infection classification and guideline compliance data were collected on the 30 prescriptions in the participating hospitals. Results: A total of 2619 patient records were reviewed. Of these, 249 (9.5%) patients were discharged with antimicrobial prescriptions from the ED. Most (158; 63%) were classified as probable bacterial infection, 21 (8%) as probable viral, and 18 (7%) had no documented evidence of infection. Three indications accounted for 73% of antimicrobial prescriptions: skin/soft tissue infection; ear, nose and throat infection; and urinary tract infection. Overall guideline compliance was 64%. Conclusions: Several areas for AMS interventions to optimize antimicrobial prescribing in the ED were identified, including targeted local and national guideline reviews, delayed prescribing, improved point-of-care testing and prescriber and patient education.
- Open Access
- 21 November 2022
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 71 (10) , 001606
Haemophilus influenzae type f in the post-Haemophilus influenzae type b vaccination era: a systematic review
Since the introduction of Haemophilus influenzae (Hi) serotype b (Hib) vaccination, reports of increasing incidence rates of non-Hib serotypes have emerged. A systematic review was performed to investigate whether the Hi serotype f (Hif) incidence rate has increased globally and to describe its associated disease burden. In the post-Hib vaccine era, evidence shows that the incidence rate of Hif infection is increasing worldwide. In total 94 studies including 2 701 patients reported Hif infections. The estimated pooled incidence rate of Hif infection was 0.15/100 000 population per year (range: 0.05–0.40/100 000), with a median case fatality ratio of 14.3 %. Invasive infections most frequently presented as pneumonia (45 %), septicaemia (34 %) and meningitis (20 %). Of 191 Hif isolates, 87 % were ampicillin-susceptible. Multi-locus sequence typing revealed that Hif were relatively clonal, with the majority belonging to clonal complex 124. Hif causes invasive infections of significant variance in both severity and presentation. Globally, the Hif population shows little genetic variability and currently appears to possess low resistance to antimicrobials.
- 21 November 2022
- Published by Microbiology Society in Journal of Medical Microbiology
- Vol. 71 (10) , 001606
Open AccessHaemophilus influenzae type f in the post-Haemophilus influenzae type b vaccination era: a systematic review
Since the introduction of Haemophilus influenzae (Hi) serotype b (Hib) vaccination, reports of increasing incidence rates of non-Hib serotypes have emerged. A systematic review was performed to investigate whether the Hi serotype f (Hif) incidence rate has increased globally and to describe its associated disease burden. In the post-Hib vaccine era, evidence shows that the incidence rate of Hif infection is increasing worldwide. In total 94 studies including 2 701 patients reported Hif infections. The estimated pooled incidence rate of Hif infection was 0.15/100 000 population per year (range: 0.05–0.40/100 000), with a median case fatality ratio of 14.3 %. Invasive infections most frequently presented as pneumonia (45 %), septicaemia (34 %) and meningitis (20 %). Of 191 Hif isolates, 87 % were ampicillin-susceptible. Multi-locus sequence typing revealed that Hif were relatively clonal, with the majority belonging to clonal complex 124. Hif causes invasive infections of significant variance in both severity and presentation. Globally, the Hif population shows little genetic variability and currently appears to possess low resistance to antimicrobials.
- 6 April 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 41 (7) , 587-589
Emergence of Congenital Chagas Disease in Ireland
Chagas disease (CD) is an under-diagnosed tropical disease that is increasingly being observed outside of Latin America. We describe the first 2 infants with congenital Chagas Disease (cCD) in Ireland. Clinicians in nonendemic countries need to be aware of the potential for cCD due to the migration of women from countries of high prevalence.
- 6 April 2022
- Published by Wolters Kluwer Health in The Pediatric Infectious Disease Journal
- Vol. 41 (7) , 587-589
Emergence of Congenital Chagas Disease in Ireland
Chagas disease (CD) is an under-diagnosed tropical disease that is increasingly being observed outside of Latin America. We describe the first 2 infants with congenital Chagas Disease (cCD) in Ireland. Clinicians in nonendemic countries need to be aware of the potential for cCD due to the migration of women from countries of high prevalence.